Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
  1. Home
  2. Publications
  3. Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Authors:
  • IOIzuchukwu F. Okpalanwaka
    Izuchukwu F. Okpalanwaka
  • Elizabeth A. Daugherity
    Elizabeth A. Daugherity
  • AMAmanda L. McCormick
    Amanda L. McCormick
  • TATrevor S. Anderson
    Trevor S. Anderson
  • SSSavanna L. Smith
    Savanna L. Smith
  • CLCaryn Lawrence
    Caryn Lawrence
  • DADuke Appiah
    Duke Appiah
  • DLDevin B. Lowe
    Devin B. Lowe

Open Access
Publisher website
Google Scholar
  • 1 August 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1535-7163.29760650
Abstract
Supplementary Figure 2 details PD-L1 expression is not observably altered following REG exposure.
Keywords
  • SUPPLEMENTARY FIGURE
  • BISPECIFIC ANTIBODY
  • ANTIBODY ENHANCES
  • ANTITUMOR EFFECTS
  • COLON CANCER
  • REG EXPOSURE
  • CANCER SUPPLEMENTARY
  • FIGURE
  • OBSERVABLY ALTERED
  • DETAILS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.